Glioma-associated endothelial cells are chemoresistant to temozolomide
- 310 Downloads
Temozolomide is considered the standard of care and drug of choice for the treatment of initially diagnosed malignant gliomas. Although well tolerated, temozolomide still has limited clinical efficacy. Following drug treatment, patient prognosis still remains poor; tumor recurrence is almost universal. We hypothesized that this lack of effectiveness with temozolomide is because this drug does not target the glioma microenvironment, which is highly vascular in malignant gliomas. To test this hypothesis we analyzed the effects of temozolomide on the tumor vasculature in vitro and in vivo. We found that this drug did not affect the viability or proliferation rate of endothelial cells isolated from human glioma specimens, although temozolomide was highly cytotoxic to the glioma cell lines U87MG and U251. Furthermore, temozolomide did not inhibit the migration of these glioma-associated endothelial cells, a key mechanism responsible for tumor angiogenesis. In in vivo studies, using the intracranial glioma mouse model, temozolomide did not cause a pronounced effect on microvessel density. Our findings show that temozolomide has no apparent effect on the glioma vascular microenvironment. Thus combination therapy with anti-vascular agents may enhance temozolomide effectiveness as glioma therapeutic protocol.
KeywordsTemozolomide Endothelial cells Glioblastoma multiforme Angiogenesis
We would like to thank the members of the Glioma Research Group at the Keck School of Medicine, University of Southern California for insightful discussions. This work was funded by the Whittier Foundation, USC/Norris Cancer Center and the Sounder Foundation.
- 13.Gately S, Li WW (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31(2 Suppl 7):22–29Google Scholar
- 19.Batista LF, Roos WP, Christmann M et al (2007) Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 67(24):11886–11895. doi: 10.1158/0008-5472.CAN-07-2964 CrossRefPubMedGoogle Scholar
- 22.Miyagami M, Katayama Y (2005) Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel–Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein. Med Mol Morphol 38:36–42. doi: 10.1007/s00795-004-0273-0 CrossRefPubMedGoogle Scholar